Dyno Therapeutics announced a licensing and collaboration deal with Roche worth up to $1.8 billion to apply the Cambridge, Mass.-based company’s CapsidMap platform to the development of adeno-associated virus (AAV) vectors for gene therapies for central nervous system diseases and liver-directed therapies.

Cambridge, Massachusetts-based Dyno Therapeutics came out of stealth mode with an official launch of the company’s proprietary CapsidMap platform.